EyePoint Sues Ocular for False Claims on Duravyu
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 21 2026
0mins
Should l Buy EYPT?
Source: seekingalpha
- Lawsuit Background: EyePoint (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) in a Massachusetts federal court, alleging that Ocular made false or misleading claims about Duravyu's clinical findings, impacting market perceptions of both companies' products.
- Drug Development Competition: Duravyu is currently in late-stage development targeting wet age-related macular degeneration (wet AMD), which is also the focus of Ocular's lead asset, Axpaxli, creating a direct competitive landscape between the two firms.
- Legal Demands: EyePoint seeks an injunction to prevent Ocular from continuing the alleged dissemination of false claims, along with a retraction of statements and financial damages, highlighting its commitment to protecting its reputation and market position.
- Industry Impact: This lawsuit could significantly affect the future market performance of both companies, particularly in the ophthalmic drug sector, where intensified competition may lead to fluctuations in investor confidence regarding their stocks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EYPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EYPT
Wall Street analysts forecast EYPT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.410
Low
20.00
Averages
31.50
High
43.00
Current: 13.410
Low
20.00
Averages
31.50
High
43.00
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EyePoint (EYPT) Q1 2026 Earnings Transcript
See More
EyePoint Pharmaceuticals Q1 2026 Earnings Call Insights
- Declining Financial Performance: EyePoint reported total net revenue of $0.7 million for Q1 2026, a significant drop from $24.5 million in Q1 2025, primarily due to the recognition of remaining deferred revenue from the YUTIQ licensing agreement, indicating pressure on the company's revenue streams.
- Robust R&D Progress: The company maintained a low discontinuation rate of about 5% in its wet AMD program, well below the industry average of 10%, with over 35% of patients having received their third planned dose of DURAVU by week 56, demonstrating strong execution and patient adherence in clinical trials.
- Tightening Cash Position: As of March 31, 2026, EyePoint's cash and investments totaled $223 million, down from $306 million at the end of 2025, raising concerns about the sustainability of operations despite management's expectation to fund operations into Q4 2027 amid increasing cash burn.
- Clinical Trial Advancements: EyePoint is seeing strong momentum in its DME program, with expectations to achieve full enrollment in both pivotal trials by Q3 2026, and over one-third of patients already enrolled, reflecting effective utilization of its clinical trial infrastructure and investigator network.
See More
EyePoint Pharmaceuticals to Announce Q1 Earnings on May 6
- Earnings Announcement: EyePoint Pharmaceuticals is set to release its Q1 2023 earnings on May 6 before market open, with a consensus EPS estimate of -$0.81, reflecting a 24.6% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations: The anticipated revenue for Q1 is $0.35 million, down 98.6% year-over-year, highlighting severe competitive pressures that could undermine investor confidence moving forward.
- Performance Track Record: Over the past year, EyePoint has beaten EPS estimates 50% of the time and has exceeded revenue estimates 100% of the time, suggesting a degree of stability in revenue management despite broader challenges.
- Revision Trends: In the last three months, there have been no upward revisions to EPS estimates and four downward revisions, while revenue estimates also saw no upward revisions with one downward adjustment, reflecting analysts' cautious outlook on the company's future performance.
See More
Arvinas Shares Surge 6.9% on Positive Pipeline Expectations
- Price Surge Reason: Arvinas, Inc. shares rose 6.9% in the last trading session to close at $11.33, with trading volume significantly exceeding normal levels, reflecting positive investor expectations despite a 20.7% decline over the past four weeks.
- Clinical Trial Data: The company presented encouraging early-stage data for ARV-102, showing that treatment achieved a 50% or greater reduction of LRRK2 in cerebrospinal fluid at all doses by day 14, maintaining this reduction through day 28, indicating strong therapeutic potential for Parkinson's disease.
- Earnings Report Expectations: The upcoming quarterly report is expected to show a loss of $0.94 per share, representing a year-over-year decline of 182.5%, with revenues projected at $17.09 million, down 91% from the previous year, highlighting significant financial challenges ahead for the company.
- Earnings Estimate Revisions: Over the last 30 days, the consensus EPS estimate for Arvinas has been revised 1.3% lower, and negative trends in earnings estimate revisions typically do not bode well for stock price appreciation, prompting investors to monitor ARVN's future performance closely.
See More
EyePoint Sues Ocular for False Claims on Duravyu
- Lawsuit Background: EyePoint (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) in a Massachusetts federal court, alleging that Ocular made false or misleading claims about Duravyu's clinical findings, impacting market perceptions of both companies' products.
- Drug Development Competition: Duravyu is currently in late-stage development targeting wet age-related macular degeneration (wet AMD), which is also the focus of Ocular's lead asset, Axpaxli, creating a direct competitive landscape between the two firms.
- Legal Demands: EyePoint seeks an injunction to prevent Ocular from continuing the alleged dissemination of false claims, along with a retraction of statements and financial damages, highlighting its commitment to protecting its reputation and market position.
- Industry Impact: This lawsuit could significantly affect the future market performance of both companies, particularly in the ophthalmic drug sector, where intensified competition may lead to fluctuations in investor confidence regarding their stocks.
See More
EYEPOINT INC - SEC Filing Claims Ocular Therapeutix Made False Statements About EYEPOINT and DURAVYU
Complaint Overview: A complaint has been filed against EyePoint Pharmaceuticals, alleging that the company disseminated false statements regarding its products, specifically related to EyePoint and Duravyu.
Allegations Details: The allegations focus on claims made by EyePoint that are said to misrepresent the efficacy and safety of their therapeutic offerings, potentially misleading stakeholders and consumers.
See More
EyePoint (EYPT) Q1 2026 Earnings Transcript
See More
EyePoint Pharmaceuticals Q1 2026 Earnings Call Insights
- Declining Financial Performance: EyePoint reported total net revenue of $0.7 million for Q1 2026, a significant drop from $24.5 million in Q1 2025, primarily due to the recognition of remaining deferred revenue from the YUTIQ licensing agreement, indicating pressure on the company's revenue streams.
- Robust R&D Progress: The company maintained a low discontinuation rate of about 5% in its wet AMD program, well below the industry average of 10%, with over 35% of patients having received their third planned dose of DURAVU by week 56, demonstrating strong execution and patient adherence in clinical trials.
- Tightening Cash Position: As of March 31, 2026, EyePoint's cash and investments totaled $223 million, down from $306 million at the end of 2025, raising concerns about the sustainability of operations despite management's expectation to fund operations into Q4 2027 amid increasing cash burn.
- Clinical Trial Advancements: EyePoint is seeing strong momentum in its DME program, with expectations to achieve full enrollment in both pivotal trials by Q3 2026, and over one-third of patients already enrolled, reflecting effective utilization of its clinical trial infrastructure and investigator network.
See More
EyePoint Pharmaceuticals to Announce Q1 Earnings on May 6
- Earnings Announcement: EyePoint Pharmaceuticals is set to release its Q1 2023 earnings on May 6 before market open, with a consensus EPS estimate of -$0.81, reflecting a 24.6% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations: The anticipated revenue for Q1 is $0.35 million, down 98.6% year-over-year, highlighting severe competitive pressures that could undermine investor confidence moving forward.
- Performance Track Record: Over the past year, EyePoint has beaten EPS estimates 50% of the time and has exceeded revenue estimates 100% of the time, suggesting a degree of stability in revenue management despite broader challenges.
- Revision Trends: In the last three months, there have been no upward revisions to EPS estimates and four downward revisions, while revenue estimates also saw no upward revisions with one downward adjustment, reflecting analysts' cautious outlook on the company's future performance.
See More
Arvinas Shares Surge 6.9% on Positive Pipeline Expectations
- Price Surge Reason: Arvinas, Inc. shares rose 6.9% in the last trading session to close at $11.33, with trading volume significantly exceeding normal levels, reflecting positive investor expectations despite a 20.7% decline over the past four weeks.
- Clinical Trial Data: The company presented encouraging early-stage data for ARV-102, showing that treatment achieved a 50% or greater reduction of LRRK2 in cerebrospinal fluid at all doses by day 14, maintaining this reduction through day 28, indicating strong therapeutic potential for Parkinson's disease.
- Earnings Report Expectations: The upcoming quarterly report is expected to show a loss of $0.94 per share, representing a year-over-year decline of 182.5%, with revenues projected at $17.09 million, down 91% from the previous year, highlighting significant financial challenges ahead for the company.
- Earnings Estimate Revisions: Over the last 30 days, the consensus EPS estimate for Arvinas has been revised 1.3% lower, and negative trends in earnings estimate revisions typically do not bode well for stock price appreciation, prompting investors to monitor ARVN's future performance closely.
See More
EyePoint Sues Ocular for False Claims on Duravyu
- Lawsuit Background: EyePoint (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) in a Massachusetts federal court, alleging that Ocular made false or misleading claims about Duravyu's clinical findings, impacting market perceptions of both companies' products.
- Drug Development Competition: Duravyu is currently in late-stage development targeting wet age-related macular degeneration (wet AMD), which is also the focus of Ocular's lead asset, Axpaxli, creating a direct competitive landscape between the two firms.
- Legal Demands: EyePoint seeks an injunction to prevent Ocular from continuing the alleged dissemination of false claims, along with a retraction of statements and financial damages, highlighting its commitment to protecting its reputation and market position.
- Industry Impact: This lawsuit could significantly affect the future market performance of both companies, particularly in the ophthalmic drug sector, where intensified competition may lead to fluctuations in investor confidence regarding their stocks.
See More
EYEPOINT INC - SEC Filing Claims Ocular Therapeutix Made False Statements About EYEPOINT and DURAVYU
Complaint Overview: A complaint has been filed against EyePoint Pharmaceuticals, alleging that the company disseminated false statements regarding its products, specifically related to EyePoint and Duravyu.
Allegations Details: The allegations focus on claims made by EyePoint that are said to misrepresent the efficacy and safety of their therapeutic offerings, potentially misleading stakeholders and consumers.
See More
